ITN TrialShare: Promoting reproducible research and transparency in clinical trials Adam Asare, PhD Director, Data Analysis 12/11/2012.

Slides:

Advertisements

Similar presentations

University of Sydney – Academic Forum – 13 April 2005 John Shipp University Librarian THE FUTURE OF THE UNIVERSITY LIBRARY CHANGES IN SCHOLARLY COMMUNICATION.

Advertisements

Type 2 Translational Research Funding Programs External Community Review Committee Introduction for New Members Maureen A Smith, MD MPH PhD Associate Director.

Vaxil BioTherapeutics Ltd.

Improving Quality of Trials through the MRC Network of Hubs for Trials Methodology Research Professor Lucinda (Cindy) Billingham Professor of Biostatistics.

Financial Conflicts of Interest in Medical Research Karen Santoro Deputy Ethics Counselor National Institute of Allergy and Infectious Diseases.

What’s NIH? National Cancer Institute National Eye Institute National Heart, Lung, and Blood Inst. National Human Genome Research Inst National Institute.

Optimization of Preclinical Animal Models Steven Perrin, PhD CEO, CSO ALS Therapy Development Institute.

ACCELERATING CLINICAL AND TRANSLATIONAL RESEARCH Anantha Shekhar MD, PhD Indiana University School of Medicine Indiana Clinical and.

EBI Proteomics Services Team – Standards, Data, and Tools for Proteomics Henning Hermjakob European Bioinformatics Institute SME forum 2009 Vienna.

Service activities ViBRANT Project Year 3/Final Review Meeting – Brussels Description & Objectives WP Description WP Objectives WP partners.

The Cost-Effectiveness of Providing DAFNE to Subgroups of Predicted Responders J Kruger 1, A Brennan 1, P Thokala 1, S Heller 2 on behalf of the DAFNE.

Philip J. Ditchfield Manager, Contracts & Licensing GlaxoSmithKline Data Mining and the Pharmaceutical Industry.

Medical Diagnostics NIAID Funding Opportunities Maria Y. Giovanni, Ph.D. Assistant Director for Microbial Genomics and Advanced Technologies National Institute.

Five Slides About EGAN Jesse Paquette UCSF Helen Diller Family Comprehensive Cancer Center

Center of Innovation for Biomaterials in Orthopaedic Research (C.I.B.O.R.) Paul H. Wooley, Ph.D. Director, Orthopaedic Research Institute KBA Eminent Scholar.

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.

FROM DATA REPOSITORIES TO DATA JOURNALS – WHERE, WHEN AND HOW TO SUBMIT Andrew L. Hufton Managing Editor, Scientific Data Nature Publishing Group

Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.

NIHR CLAHRC for South Yorkshire What is NIHR CLAHRC? Collaborations for Leadership in Applied Health Research & Care Conduct research, implementation and.

Monitoring Adverse Events using an Interactive Web-Based Tool Ryan Bailey Rho, Inc.

121 Intramural Biomedical Projects in Rare Diseases (PIBER) Support Platforms for Research into Rare Diseases (PITER) Management Office Scientific Director.

Models of Collaboration and Open Science Summit 2015 Suzana Petanceska PhD National Institute on Aging Accelerating Medicines Partnership for Alzheimer’s.

Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.

Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.

BioSciencs Foro November 8th, New York Joaquin Guinea Chairman of BIOMADRID (

Expanding Access to OpenClinica Data via LabKey Server Peter Hussey 2013 OpenClinica Global Conference Founding Partner, LabKey Software June 21, 2013.

BIOMARKER STUDIES IN CLINICAL TRIALS Vicki Seyfert-Margolis, PhD.

Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.

A centre of expertise in digital information management UKOLN is supported by: Monica Duke Project.

Natural History of Type 1 Diabetes CELLULAR (T CELL) AUTOIMMUNITY LOSS OF FIRST PHASE INSULIN RESPONSE (IVGTT) (IVGTT) GLUCOSE INTOLERANCE (OGTT) HUMORAL.

Sage Bionetworks A non-profit organization with a vision to enable networked team approaches to building better models of disease BIOMEDICINE INFORMATION.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FITBIR: A Platform for International.

1 Positioning Canada as a Global Leader in Healthcare Delivery through ICT Repeatable Public-Private Model May 27, 2013.

The South East Wales Academic Health Science Partnership Dr Corinne Squire Manager SEWAHSP.

ODD-Genes: Accelerating data-driven scientific discovery NeSC Review 2003 NeSC

NanoHUB.org and HUBzero™ Platform for Reproducible Computational Experiments Michael McLennan Director and Chief Architect, Hub Technology Group and George.

September 7 th 2011 Meeting needs, making changes, improving outcomes.

Sage Bionetworks A non-profit organization with a vision to enable networked team approaches to building better models of disease BIOMEDICINE INFORMATION.

National Center for Research Resources G. Iris Obrams, M.D., M.P.H., Ph.D. NCRR Update 5 August 2006.

Karen A. Blase, PhD, Allison Metz, PhD and Dean L. Fixsen, PhD Frank Porter Graham Child Development Institute University of North Carolina at Chapel Hill.

University of Kentucky Center for Clinical and Translational Science (CCTS) November 2015 Stephen W. Wyatt, DMD, MPH Senior Associate Director Center for.

MRC Technology an independent life science medical research charity Biotech & Money 2016 Mr Andrew Mercieca, Director of Finance

1 ITN clinical trial analysis design – Transplantation example Cross-sectional and longitudinal clinical trials to assess tolerance Disease areas: Transplantation.

Ukpmc.ac.uk As a result of the mandates Research in the open How mandates work in practice 29 th May, 2009 Paul Davey, UK PubMed Central Engagement Manager,

Practical Steps for Increasing Openness and Reproducibility Courtney Soderberg Statistical and Methodological Consultant Center for Open Science.

1 Trends in drug development programs in the era of Personalized Medicine Gunnar Saeter, M.D., Ph.D. Head, Institute for Cancer Research Oslo University.

Practical Steps for Increasing Openness and Reproducibility Courtney Soderberg Statistical and Methodological Consultant Center for Open Science.

Coming Soon – the MRC Framework for the Development, Design and Analysis of Stratified Medicine Research Dr David Crosby MRC Programme Manager for Methodology.

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiovascular Drug Development: Is it Dead or Just.

University of Virginia Innovation – How to Make Your Grant New and Unique Grant Writing Workshop American Association for Thoracic Surgery David R. Jones.

Lisa Hussey Associate Publisher, Clinical Medicine 4 th March 2016 Born open access – a new approach to publishing and science.

OMICS international Contact us at: OMICS International through its Open Access Initiative is committed to make genuine and.

Office of Commercialization Dr. Sita Pappu, Director January 31, 2017

Placebo / Standard of Care (PSoC)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Non For Profit Model for Rare Disease Therapy Development

Nat. Rev. Neurol. doi: /nrendo

Nat. Rev. Rheumatol. doi: /nrrheum

Novara Italy Expertise in:

Figure 3 Proportion of patients for whom NEDA

Gene Therapy: Past, Present, and Future

Nat. Rev. Cardiol. doi: /nrcardio

Evolving Gene Therapy in Primary Immunodeficiency

Carolina Mendoza-Puccini, MD

Overview of Clinical & Translational Penn

Figure 3 Multi-hit model for autoimmune diseases

The Vision The UK and partner countries, through the Newton Fund, will continue to build on existing science and innovation partnerships to promote the.

Target disease and target populations for 21st century vaccine developmentIncluded in the list are the agents of infectious diseases for which vaccines.

Presentation transcript:

ITN TrialShare: Promoting reproducible research and transparency in clinical trials Adam Asare, PhD Director, Data Analysis 12/11/2012

Reproducibility of results in published literature 2 Ionnidis, P. et al. Repeatability of published microarray gene expression analyses. Nat Gen, 41:2, Feb 2009

Immune Tolerance Network(ITN) Clinical trials consortium whose mission is to accelerate the development of immune tolerance therapies – Therapeutic areas include: allergy/asthma, transplantation, and autoimmune diseases – Over 50 Phase I/II clinical trials – NIH/NIAID funded for over 12 years, ~30M/year – Numerous academic and industry partners Core objectives: Innovation & Collaboration – Develop novel assay technologies – Support rigorous and reproducible research – Adhere to standardized platforms and processes – Use best practices approach to statistical methodology – Disseminate data and results to research community

Web access to data and analyses: itntrialshare.org

Data analysis study archive

Manuscript figures and analysis code console Download data and code base Re-run analysis within system Original Analysis User-defined analysis figure and output Data Code

Create a new paradigm for research publishing – Generate high-profile manuscripts that are interactive at the data and code level Query for information regarding how the published data was generated Allow exploration of alternative analysis approaches – Benefits realized Allows rapid review of data and analysis approaches by study team internally for manuscript development Public resource available to the research community for reference datasets and analysis approaches – Expect additional functionality to be phased in over time

Funding Attribution Slide: General ITN National Institute of Diabetes & Digestive & Kidney Diseases FUNDED BY: National Institute of Allergy & Infectious Diseases Food Allergy Initiative